Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PRKCD_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PRKCD_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PRKCD_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PRKCD_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PRKCD_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PRKCD_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003367319 | Esophagus | ESCC | negative regulation of kinase activity | 154/8552 | 237/18723 | 1.38e-09 | 3.27e-08 | 154 |
GO:000646920 | Esophagus | ESCC | negative regulation of protein kinase activity | 140/8552 | 212/18723 | 1.53e-09 | 3.56e-08 | 140 |
GO:004348819 | Esophagus | ESCC | regulation of mRNA stability | 109/8552 | 158/18723 | 2.40e-09 | 5.35e-08 | 109 |
GO:0042542111 | Esophagus | ESCC | response to hydrogen peroxide | 102/8552 | 146/18723 | 2.64e-09 | 5.81e-08 | 102 |
GO:000647018 | Esophagus | ESCC | protein dephosphorylation | 177/8552 | 281/18723 | 3.13e-09 | 6.72e-08 | 177 |
GO:0051258111 | Esophagus | ESCC | protein polymerization | 183/8552 | 297/18723 | 1.94e-08 | 3.75e-07 | 183 |
GO:0051100111 | Esophagus | ESCC | negative regulation of binding | 109/8552 | 162/18723 | 2.10e-08 | 4.03e-07 | 109 |
GO:000701527 | Esophagus | ESCC | actin filament organization | 259/8552 | 442/18723 | 2.37e-08 | 4.50e-07 | 259 |
GO:007147816 | Esophagus | ESCC | cellular response to radiation | 122/8552 | 186/18723 | 3.07e-08 | 5.73e-07 | 122 |
GO:003253520 | Esophagus | ESCC | regulation of cellular component size | 227/8552 | 383/18723 | 4.77e-08 | 8.60e-07 | 227 |
GO:0008631110 | Esophagus | ESCC | intrinsic apoptotic signaling pathway in response to oxidative stress | 38/8552 | 45/18723 | 8.42e-08 | 1.43e-06 | 38 |
GO:0035304111 | Esophagus | ESCC | regulation of protein dephosphorylation | 66/8552 | 90/18723 | 8.82e-08 | 1.48e-06 | 66 |
GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
GO:0035303111 | Esophagus | ESCC | regulation of dephosphorylation | 88/8552 | 128/18723 | 1.04e-07 | 1.71e-06 | 88 |
GO:003461420 | Esophagus | ESCC | cellular response to reactive oxygen species | 103/8552 | 155/18723 | 1.34e-07 | 2.17e-06 | 103 |
GO:190458914 | Esophagus | ESCC | regulation of protein import | 49/8552 | 63/18723 | 1.91e-07 | 2.97e-06 | 49 |
GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
GO:190459116 | Esophagus | ESCC | positive regulation of protein import | 36/8552 | 43/18723 | 2.90e-07 | 4.20e-06 | 36 |
GO:0032970111 | Esophagus | ESCC | regulation of actin filament-based process | 231/8552 | 397/18723 | 2.91e-07 | 4.20e-06 | 231 |
GO:0032956111 | Esophagus | ESCC | regulation of actin cytoskeleton organization | 210/8552 | 358/18723 | 4.40e-07 | 6.00e-06 | 210 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKCD | SNV | Missense_Mutation | novel | c.1115N>T | p.Gly372Val | p.G372V | Q05655 | protein_coding | deleterious(0.01) | benign(0.342) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
PRKCD | SNV | Missense_Mutation | novel | c.548A>T | p.Asn183Ile | p.N183I | Q05655 | protein_coding | deleterious(0.03) | probably_damaging(0.985) | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCD | SNV | Missense_Mutation | | c.1573N>A | p.Tyr525Asn | p.Y525N | Q05655 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A24K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PRKCD | SNV | Missense_Mutation | rs781980599 | c.277N>A | p.Glu93Lys | p.E93K | Q05655 | protein_coding | deleterious(0.02) | benign(0.407) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
PRKCD | SNV | Missense_Mutation | novel | c.609N>C | p.Lys203Asn | p.K203N | Q05655 | protein_coding | tolerated(0.21) | possibly_damaging(0.811) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
PRKCD | insertion | Frame_Shift_Ins | novel | c.1528_1529insAGGAGAAGCAGAGGCTGCTC | p.Gly510GlufsTer21 | p.G510Efs*21 | Q05655 | protein_coding | | | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PRKCD | insertion | Frame_Shift_Ins | novel | c.1989_1990insA | p.Ser664IlefsTer22 | p.S664Ifs*22 | Q05655 | protein_coding | | | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PRKCD | insertion | Nonsense_Mutation | novel | c.1990_1991insTTTAAAATATAAGTTCAGGCCGGGCACAGTGGC | p.Ser664delinsPheTerAsnIleSerSerGlyArgAlaGlnTrpPro | p.S664delinsF*NISSGRAQWP | Q05655 | protein_coding | | | TCGA-BH-A0BD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PRKCD | SNV | Missense_Mutation | rs149165175 | c.604G>A | p.Asp202Asn | p.D202N | Q05655 | protein_coding | tolerated(0.07) | benign(0.105) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRKCD | SNV | Missense_Mutation | rs782258819 | c.422N>T | p.Thr141Met | p.T141M | Q05655 | protein_coding | tolerated(0.12) | benign(0.107) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | TAE-684 | TAE-684 | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | [3H]-PHORBOL 12,13-DIBUTYRATE | CHEMBL27768 | 24794745 |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | GO-6976 | GO-6976 | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | ETHANOL | ALCOHOL | 1744136 |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL565612 | SOTRASTAURIN | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | inhibitor | 178101947 | RUBOXISTAURIN | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | ENOXOLONE | ENOXOLONE | 24461294 |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL574737 | UCN-01 | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | | KAI-9803 | DELCASERTIB | |
5580 | PRKCD | ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR | inhibitor | CHEMBL608533 | MIDOSTAURIN | |